asa guidelines for glp-1 2025 ADS/ANZCA/GESA/NACOS clinical practice recommendations on the peri-procedural use of GLP-1/GIP receptor agonists How should we approach patients

Orders ship from Ontario, Canada

Healthcare providers should engage patients in shared decision-making regarding treatment duration, establishing clear goals at treatment initiation and regularly reassessing the need for continued therapy

Most users experience mild side effects, such as headaches or flushing, which are generally manageable and diminish over time

In muscle-to-tendon junction injury models, therapy restored tissue continuity within six weeks without ectopic bone formation

GLP-1 medications remain a safe and effective option for managing type 2 diabetes and obesity for the majority of the population, but its crucial to evaluate each patients risk profile before starting treatment